Shedding light on a rare disease: the first national study of Fanconi Anaemia

Fanconi anaemia (FA) is a rare genetic disorder that predisposes individuals to early onset cancer and insufficient blood production. Alongside the physical health challenges, the condition brings significant psychosocial burdens, affecting the quality of life for patients and their families.

FA has remained largely invisible in Australia. Until now, no one could answer basic but critical questions: who are the people living with FA in this country, and how many are there?

This lack of data has had real consequences. Without a clear understanding of the patient population, Australia has been poorly positioned to attract clinical trials or investment from pharmaceutical and research organisations.

A new study has changed that. By analysing 14 years of national diagnostic data, researchers have defined the first state and territory estimates of FA and uncovered strong evidence that FA is under-diagnosed in Australia. These findings make a compelling case for increasing awareness and testing for FA among clinicians.

The study also marks a major milestone: the establishment of the first-ever cohort of individuals in Australia and New Zealand with a confirmed FA diagnosis. Until now, knowledge of FA in this region was limited to a handful of isolated case reports. By examining the genetic and clinical characteristics of this group, researchers identified both similarities and differences with international data.

Notably, the study confirmed cases of FA among Aboriginal Australians, a vital reminder that clinical care and research must be inclusive and culturally sensitive.

Associate Professor Wayne Crismani, who led the research, said:

“The self-identified ancestries reported in our study reflect Australia’s multicultural population, including representation from First Nations peoples.

“We anticipate that our study lays the groundwork for future clinical trials for Fanconi anaemia in Australasia.

“By increasing awareness of FA, we aim to support earlier diagnosis and intervention, which will lead to better health outcomes for individuals and families. In turn, improved outcomes will reduce the overall burden on the healthcare system.”